t
On 22 December 2025, the European Commission granted EU marketing authorisation for ECOVAXXIN® MS, ECO Animal Health Group plc's poultry vaccine against *Mycoplasma synoviae*. This authorisation was issued over a month earlier than anticipated, following a Positive Opinion in November 2025.
| Date | 22 Dec 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 3682M |
22 December 2025
ECO Animal Health Group plc
("ECO" or the "Company")
EU marketing authorisation granted for ECOVAXXIN® MS
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that the European Commission has adopted a decision granting EU marketing authorisation (MA) for ECOVAXXIN® MS, the Company's poultry vaccine against Mycoplasma synoviae.
The MA has been issued over a month earlier than anticipated following the Committee for Medicinal Products for Veterinary Use's Positive Opinion in November 2025.
ECOVAXXIN® MS provides active immunisation of future layer and breeder chickens from four weeks of age, helping to reduce air-sac and foot-pad lesions and egg production losses caused by Mycoplasma synoviae infections. The infection causes economic loss, especially in laying hens, and the number of eggs produced by affected layers can be reduced by 5-10%.
The Company will issue an update to the market in early 2026 to provide further details on its plans for the EU commercial launch of ECOVAXXIN® MS.
David Hallas, Chief Executive Officer of ECO Animal Health, said: "We are delighted to have received EU marketing authorisation for ECOVAXXIN MS, over a month ahead of schedule. This is a key milestone for ECO, enabling the first commercial launch from our innovative R&D portfolio, and reflects the high-quality work from our R&D, regulatory, marketing, and technical teams.
"We look forward to updating the market early in 2026 to provide more detail on our plans for the commercial launch of this important vaccine."
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
020 8447 8899 |
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson |
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Samed Ethemi
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000 |
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com